Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation.

However, the primary end point showed a positive trend towards improvement after adjusting for the baseline, especially in more severely affected patients.

also in 11,005 other papers

The RCT primary end point [change from placebo in the attentional domain of the cognition score (visual identification; Cogstate IDN)] did not reach statistical significance.

also in 111,027 other papers